FDA Grants Orphan-Drug Designation to Mesoblast's Revascor® for Congenital Heart Disease in Children

Mesoblast's Chief Executive, Silviu Itescu, expressed satisfaction with the FDA's decision: “We are very pleased to have now been granted both Orphan...

February 15, 2024 | Thursday | News
Corvus Pharmaceuticals Receives Orphan Drug Designation for Soquelitinib in T Cell Lymphoma, Advances Towards Phase 3 Clinical Trial

Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a distinguished player in the clinical-stage biopharmaceutical arena, has achieved a significant milestone wit...

February 12, 2024 | Monday | News
Takeda Advances Global Phase 3 Trials of TAK-861 in Narcolepsy Type 1 Following Positive Phase 2b Results

Takeda  unveiled promising topline results from a comprehensive Phase 2b trial evaluating TAK-861, an oral orexin receptor 2 (OX2R) agonist, in patien...

February 12, 2024 | Monday | News
Auron Therapeutics Unveils Groundbreaking Cancer Treatment Candidate AUTX-703 from AURIGIN™ Platform

    Auron Therapeutics, a pioneering biotechnology firm dedicated to advancing targeted cancer therapies, has announced the selection of its in...

February 08, 2024 | Thursday | News
Medidata and Sanofi Vaccines Forge Deeper Collaboration to Enhance Patient Centricity and Trial Efficiency

Medidata, a Dassault Systèmes company and a leading provider of clinical trial solutions to the life sciences industry, has joined forces with Sanof...

February 07, 2024 | Wednesday | News
Junshi Biosciences Announces Toripalimab’s NDA Accepted by the Singapore Health Sciences Authority

Shanghai Junshi Biosciences Co., Ltd (“Junshi Biosciences”, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company ded...

February 02, 2024 | Friday | News
Hummingbird Diagnostics Begins Patient Registration for miLungDx Trial, a Novel Early-Stage Lung Cancer Test

Hummingbird Diagnostics GmbH, a leader in the analysis of blood-based small RNA (sRNA) for the early detection and characterization of diseases, today anno...

January 24, 2024 | Wednesday | News
InnoCare Initiates Clinical Trial for Zurletrectinib in China, Administering First Dose to Pediatric Patient

Zurletrectinib, developed by InnoCare, is a pan-TRK inhibitor which markedly inhibits the activity of the wild type TRKA, TRKB and TRKC, as well as mutant ...

January 24, 2024 | Wednesday | News
Kairos Pharma Initiates Phase 1 Trial for ENV105 in Combination with Osimertinib for Enhanced Therapy in EGFR-Driven Lung Cancer

Kairos Pharma CEO John Yu stated, “The initiation of this trial speaks to the dedication of the Kairos team to execute on its goals to develop therap...

January 17, 2024 | Wednesday | News
CELLSEARCH® CTC Count Validates Clinical Use in HR+/HER2- Metastatic Breast Cancer Care

Menarini Silicon Biosystems, a pioneer of liquid biopsy and single-cell technologies, announced the recent publication of the STIC CTC trial data demonstra...

January 16, 2024 | Tuesday | News
TransCode Therapeutics Announces Cost-Cutting Measures, Shifts Focus to Phase 1 Trial, CEO Retirement

The restructuring is intended to further reduce expenditures and enable greater concentration of company resources on a planned Phase 1 clinical trial for ...

January 15, 2024 | Monday | News
VantAI Renews Partnership with Blueprint Medicines for Innovative Drug Discovery

-- VantAI’s advanced geometric deep learning platform will be used to generate innovative proximity modulating therapeutics, including molecular glue...

January 10, 2024 | Wednesday | News
Valneva Begins Pediatric Trial for Single-Shot Chikungunya Vaccine

The Company reported positive pivotal Phase 3 data in adolescents two months ago confirming the immunogenicity and safety profile observed in adults1.There...

January 10, 2024 | Wednesday | News
Omniose Joins Forces with AstraZeneca for Breakthrough Research on Vaccines for Severe Bacterial Diseases

Omniose, a preclinical stage biotechnology company, today announced an exclusive collaboration agreement with AstraZeneca for the search for potential vacc...

January 08, 2024 | Monday | News

Survey Box

Poll of the Week

Which area of biopharmaceutical research excites you the most?

× Please select an option to participate in the poll.
Processing...
× You have successfully cast your vote.
 {{ optionDetail.option }}  {{ optionDetail.percentage }}%
 {{ optionDetail.percentage }}% Complete
More polls
Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox

© 2024 Biopharma Boardroom. All Rights Reserved.

Show

Forgot your password?

Show

Show

Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in

Close